Investment in manufacturing facilities for highly potent pharmaceuticals and stable supply
First written in FY2016. 3 of 10 entries say "Advanced", first in FY2017. Latest entry: FY2026.
0 other companies' latest entry also says "Achieved".
- FY2026AchievedAnnual report
「*2 Decrease in construction in progress: transfer of the nucleic acid active pharmaceutical ingredient purification building to the completed-asset account, ¥5,586 million (transferred to buildings, ¥3,740 million; structures, ¥82 million; machinery and equipment, ¥1,694 million; tools, fixtures and equipment, ¥68 million).」
The company disclosed the transfer of the nucleic acid active pharmaceutical ingredient purification building from construction in progress to the completed-asset account, indicating that the facility had reached the completed and operational stage. - FY2025AchievedAnnual report
「Odawara General Formulation Plant (Odawara, Kanagawa Prefecture) Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,990 5,984 Second quarter of FY2021 First quarter of FY2025」
Payments already made for the nucleic acid active pharmaceutical ingredient purification building reached ¥5,984 million against planned investment of ¥5,990 million, reaching the scheduled completion period of the first quarter of FY2025. - FY2024SoftenedAnnual report
「Odawara General Formulation Plant (Odawara, Kanagawa Prefecture) Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,990 4,597 Second quarter of FY2021 First quarter of FY2025」
Planned investment for the nucleic acid active pharmaceutical ingredient purification building increased from ¥5.6 billion to ¥5.99 billion, while payments already made reached ¥4.597 billion. The scheduled completion was postponed from the third quarter of FY2023 to the first quarter of FY2025. - FY2023AdvancedAnnual report
「Odawara General Formulation Plant Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,600 1,947 Second quarter of FY2021 Third quarter of FY2023」
Payments already made for the nucleic acid active pharmaceutical ingredient purification building reached ¥1.947 billion against planned investment of ¥5.6 billion. Completion was scheduled for the third quarter of FY2023. - FY2022-Q3RestatedAnnual report
「Odawara General Formulation Plant (Odawara, Kanagawa Prefecture) Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,600 — Second quarter of FY2021 Third quarter of FY2023」
The company reiterated the plan for the nucleic acid active pharmaceutical ingredient purification building at the Odawara General Formulation Plant, with planned investment of ¥5.6 billion, construction beginning in the second quarter of FY2021 and completion scheduled for the third quarter of FY2023. - FY2022-Q2RestatedAnnual report
「Odawara General Formulation Plant (Odawara, Kanagawa Prefecture) Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,600 — Second quarter of FY2021 Third quarter of FY2023」
The company reiterated the plan for the nucleic acid active pharmaceutical ingredient purification building at the Odawara General Formulation Plant, with planned investment of ¥5.6 billion, construction beginning in the second quarter of FY2021 and completion scheduled for the third quarter of FY2023. - FY2022-Q1AdvancedAnnual report
「Odawara General Formulation Plant (Odawara, Kanagawa Prefecture) Pharmaceuticals business Nucleic acid active pharmaceutical ingredient purification building 5,600 — Second quarter of FY2021 Third quarter of FY2023」
A new plan was finalized to construct a nucleic acid active pharmaceutical ingredient purification building at the Odawara General Formulation Plant, with planned investment of ¥5.6 billion. Construction was scheduled to begin in the second quarter of FY2021 and be completed in the third quarter of FY2023. - FY2018-Q2AchievedAnnual report
「In July this year, the highly potent solid formulation building was completed on the site of the company’s Odawara General Formulation Plant in Kanagawa Prefecture.」
The planned solid formulation building at the Odawara General Formulation Plant was completed in July 2017. - FY2017AdvancedAnnual report
「For the highly potent formulation manufacturing facility at the Odawara General Formulation Plant in Odawara, Kanagawa Prefecture, the planned investment was ¥3,337 million, with ¥1,093 million already paid. Construction began in the first half of FY2016, with completion scheduled for the second half of FY2017.」
The company reported ¥1,093 million in payments already made for the highly potent formulation manufacturing facility, indicating that the project was proceeding. - FY2016First statedAnnual report
「In the supply chain, the company will invest in manufacturing facilities for highly potent pharmaceuticals, seek to expand the manufacture of internally discovered drugs and contract manufacturing, and promote operational efficiency and cost management at each stage of procurement, manufacturing and logistics, as well as ensuring a stable product supply.」
The company stated that the planned investment in the highly potent formulation manufacturing facility at the Odawara General Formulation Plant was ¥3.337 billion, with work scheduled to begin in the first half of FY2016 and completion in the second half of FY2017.